Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • devorevo
    Junior Member
    • Apr 2016
    • 2

    #1

    48 v 96 multiplexing

    I have approximately 200 samples I'm planning to sequence. I originally planed on multiplexing (Illumina Nextera XT) 96 samples to make two libraries, and then sequence a library per lane for a total of two lanes. I talked to someone in our core facility about the plan and they recommended we multiplex to a maximum of 46 samples (which would then require 4 lanes total...doubling our sequencing costs) due to the possibility of some samples becoming over/underrepresented in number of reads.

    I talked with a rep from Illumina and they said multiplexing to 96 should be fine as long as the initial sample inputs amounts are the same. We quantify our samples with Qubit HS.

    Any experience or advice on multiplexing 48 v 96?
  • fanli
    Senior Member
    • Jul 2014
    • 197

    #2
    Depends how much sequencing depth you need per sample..

    Comment

    • devorevo
      Junior Member
      • Apr 2016
      • 2

      #3
      Originally posted by fanli View Post
      Depends how much sequencing depth you need per sample..
      We're looking at a minimum of ~1M reads per sample and we plan on using a system that will generate ~330M reads per lane. Because of our lower minimum threshold, we're not too concerned if the average read is 3.4M v 6.8M.

      Comment

      • fanli
        Senior Member
        • Jul 2014
        • 197

        #4
        I'd be okay with the 96-plex then. You can always repool and sequence a third run if some samples need more depth.

        For reference, attached is the indexing breakdown we got recently from a pool of ~130 Nextera XT libraries.
        Attached Files

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
          by SEQadmin2



          Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

          Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
          ...
          10-14-2026, 09:55 AM
        • SEQadmin2
          New Genomics Technologies Take Aim at Long-Standing Limits
          by SEQadmin2


          Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

          We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
          ...
          09-28-2026, 10:25 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, Yesterday, 11:13 AM
        0 responses
        14 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, Yesterday, 10:48 AM
        0 responses
        13 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-15-2026, 10:52 AM
        0 responses
        35 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-14-2026, 05:39 AM
        0 responses
        42 views
        0 reactions
        Last Post SEQadmin2  
        Working...